Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XS-03
- Development stage
- Phase 2
- Lead developer
- NovaOnco JS Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
XS-03 is an investigational small molecule drug developed by Jiangsu Xingsheng Xinhui Pharmaceutical. It is being evaluated primarily for the treatment of advanced solid tumors with RAS mutations, including metastatic colorectal cancer. The drug is currently in Phase 1/2 clinical trials, both as a monotherapy and in combination with standard chemotherapy regimens (FOLFOX or FOLFIRI) plus bevacizumab. The main objectives of ongoing studies are to assess safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with RAS-mutated cancers. The precise molecular target and mechanism of action have not been publicly disclosed[1][4].
Beyond the preview
Go deeper on XS-03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XS-03.